Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors

Part 1 Dose-escalation: Patients must have histologically confirmed locally advanced, or metastatic solid tumors who have progressed after receiving appropriate lines of standard therapy known to potentially confer clinical benefit.

Nasopharyngeal: non-keratinizing; ≤ 2 prior lines of therapy in relapse setting; patients should have received prior chemotherapy and/or immune checkpoint blockade as per SOC.

9p24.1 Lymphomas (classic Hodgkin's, PMBCL): post first line therapy and completion of salvage regimens (including ASCT) with curative intent per SOC.

Ovarian (high-grade epithelial, fallopian tube, or primary peritoneal): platinum resistant disease defined as progression within < 6 months from completion of a platinum-based chemotherapy regimen; platinum refractory subjects are excluded (defined as disease that has recurred/progressed while receiving platinum-based frontline therapy). ≤ 3 prior lines of therapy in relapse setting; may be naive or exposed to prior checkpoint therapy; may have received prior folate receptor alpha (FRα) antibody-drug conjugate (ADC), other targeted therapies, and/or PARPi as appropriate per SOC; confirmed PD-L1 CPS ≥1.